Published on 22 Feb 2024 on GuruFocus.com via Yahoo Finance
BridgeBio Pharma Inc (BBIO) Reports Q4 and Full Year 2023 Financials, Advances Key Clinical Trials
Revenue: Reported a decrease to $9.3 million for the full year 2023 from $77.6 million in the previous year.Operating Costs and Expenses: Increased to $616.7 million for the full year 2023, up from $589.9 million in the previous year.Net Loss: Grew to $(653.3) million for the full year 2023, compared to $(484.7) million in the previous year.Cash Position: Ended the year with $393 million in cash, cash equivalents, and short-term restricted cash.Strategic Capital: Secured up to $1.25 billion from Blue Owl and CPP investments, enhancing financial flexibility.Clinical Advancements: Progressed with key clinical trials, including the Phase 3 study of infigratinib for achondroplasia and the Phase 3 study of BBP-418 for LGMD2I.
Warning! GuruFocus has detected 5 Warning Signs with BBIO.
